Affordable versions of Ozempic and similar drugs may hit Canadian markets by 2026, lowering prices and improving access for patients battling obesity and diabetes.
Affordable Alternatives to Ozempic on the Horizon
Canadian patients struggling with the high cost of weight-loss and diabetes medications may soon find relief. Generic versions of semaglutide-based drugs—such as Ozempic and Wegovy—could be available in Canada as early as January 2026, following the expiration of key pricing protections for the original manufacturer.
Why This Matters
Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, has surged in popularity for its effectiveness in managing obesity and Type 2 diabetes. However, at $400 per month, the cost is prohibitive for many Canadians. “My patients are frustrated and disappointed,” said Dr. Sanjeev Sockalingam, scientific director of Obesity Canada.
What Will Change
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic, will lose exclusive pricing rights in Canada in January 2026. This opens the door for biosimilar versions—essentially generic equivalents—to enter the market. According to Mina Tadrous, a University of Toronto pharmaceutical policy expert, at least three manufacturers are preparing applications to Health Canada.
If multiple producers are approved, the cost could drop significantly. “With three generics, the price could fall to 25% of the original—around $100 a month,” Tadrous explained.
Approval Process Underway
While no biosimilars have been approved yet, experts say the process could be swift. Since the generics are based on previously validated clinical trials, new trials are typically unnecessary. “It’s about proving equivalency in metabolism and absorption,” said Dr. Sockalingam.
Once Health Canada grants approval, generics could reach pharmacies within weeks.
Impact on Coverage and Access
Public and private drug plans are expected to embrace the lower-cost alternatives. Semaglutide is already covered under Ontario’s drug formulary for seniors, low-income individuals, and people with disabilities. Generic availability would likely extend that access.
“This could open the door for many more people who currently can’t afford these medications,” said Dr. Kaberi Dasgupta, professor of medicine at McGill University.
Supporting Safe Use
Medical experts emphasize the need for proper supervision. Semaglutide must be prescribed and monitored by healthcare professionals. “It’s not a magic fix,” Dasgupta warned. “Support for diet and physical activity is essential.” She points to the U.K., where semaglutide is paired with at least 13 hours of counselling as part of its prescription model.
Easing Drug Shortages
Wider production of biosimilars may also help ease ongoing shortages. Many patients with Type 2 diabetes have experienced interruptions due to high demand. “A biosimilar made by another company could relieve pressure on the supply chain,” said Dr. Harpreet Bajaj, an endocrinologist in Brampton, Ontario.
In some provinces, public drug plans offer better access than private ones, which often emphasize cost over coverage. Dasgupta noted that Quebec’s provincial plan sometimes provides better access to medications like semaglutide for eligible patients.
For continuous coverage and real-time updates, keep following Maple News Wire.
